How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?

IN BRIEF As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Triplitt, Curtis, Hinnen, Debbie, Valentine, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669137/
https://www.ncbi.nlm.nih.gov/pubmed/29109610
http://dx.doi.org/10.2337/cd16-0072
Descripción
Sumario:IN BRIEF As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of “follow-on” biological products is likely to increase in routine clinical practice. Health care practitioners need to be fully aware of these products and accompanying considerations if they are to make informed decisions together with their patients.

Ejemplares similares